



NDA 019938/S-072

**SUPPLEMENT APPROVAL**

Novo Nordisk Inc.  
Attention: Robert B. Clark  
Vice President - Regulatory Affairs  
P.O. Box 846  
Plainsboro, NJ 08536

Dear Mr. Clark:

Please refer to your Supplemental New Drug Application (sNDA) dated and received July 24, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Novolin R (regular, human insulin [rDNA origin] USP) injection, 100 U/mL.

We acknowledge receipt of your amendment dated December 19, 2012, containing updated labeling.

This "Prior Approval" supplemental new drug application proposes to return the ReliOn logo to the package insert. The logo was previously approved in supplement S-027 and removed with a notice of discontinuation dated October 28, 2010.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, the patient package insert and the vial Instructions for Use), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please contact Mehreen Hai, Ph.D., Regulatory Project Manager, at (301) 796-5073.

Sincerely,

*{See appended electronic signature page}*

Mary H. Parks, M.D.  
Director  
Division of Metabolism & Endocrinology Products  
Center for Drug Evaluation and Research  
Food and Drug Administration

### **ENCLOSURES:**

Novolin R Package Insert  
Novolin R Patient Package Insert (previously approved on February 27, 2012)  
Novolin R Vial Instructions for Use (previously approved on February 27, 2012)

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

MARY H PARKS  
02/07/2013